Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rankning i aktier #25853
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Aktiekurs
$15.31
Senast synkroniserad: 2024-02-29
Marknadsvärde
$45.70M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Icosavax, Inc. (ICVX)

Kategori

Aktiekurshistorik för Icosavax, Inc. (ICVX)
Högsta slutkurs: $15.31 den 2024-02-01

Lägsta slutkurs: $29.91 den 2021-07-01
Aktiekurshistorik för Icosavax, Inc. från 2021 till 2026
Årlig aktiekursutveckling
År Prestanda
2024 10.83%
2023 104.14%
2022 -70.48%
2021 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$539.14 36.71%
US
$1.04K 56.86%
NL
$120.74 -14.98%
AU
$761.87 7.04%
CH
$130.43 385.07%
US